173 related articles for article (PubMed ID: 17429445)
1. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic α-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responses.
Jiang H; Nace R; Ariail E; Ma Y; McGlinch E; Ferguson C; Fernandez Carrasco T; Packiriswamy N; Zhang L; Peng KW; Russell SJ
Mol Ther; 2024 Jan; 32(1):241-256. PubMed ID: 37927036
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
[TBL] [Abstract][Full Text] [Related]
5. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas-Unveiling Its Potential for Oncolytic Virotherapy.
Calderón-Peláez MA; Maradei Anaya SJ; Bedoya-Rodríguez IJ; González-Ipuz KG; Vera-Palacios D; Buitrago IV; Castellanos JE; Velandia-Romero ML
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675903
[TBL] [Abstract][Full Text] [Related]
6. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
Fulci G; Breymann L; Gianni D; Kurozomi K; Rhee SS; Yu J; Kaur B; Louis DN; Weissleder R; Caligiuri MA; Chiocca EA
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12873-8. PubMed ID: 16908838
[TBL] [Abstract][Full Text] [Related]
8. Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.
Dai W; Tian R; Yu L; Bian S; Chen Y; Yin B; Luan Y; Chen S; Fan Z; Yan R; Pan X; Hou Y; Li R; Chen J; Shu M
Nat Commun; 2024 Jan; 15(1):131. PubMed ID: 38167409
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells.
Li JM; Kao KC; Li LF; Yang TM; Wu CP; Horng YM; Jia WW; Yang CT
Virol J; 2013 Jul; 10():241. PubMed ID: 23876001
[TBL] [Abstract][Full Text] [Related]
10. OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses.
Zheng Y; Wang X; Ji Q; Fang A; Song L; Xu X; Lin Y; Peng Y; Yu J; Xie L; Chen F; Li X; Zhu S; Zhang B; Zhou L; Yu C; Wang Y; Wang L; Hu H; Zhang Z; Liu B; Wu Z; Li W
Cancer Lett; 2024 May; 589():216834. PubMed ID: 38537773
[TBL] [Abstract][Full Text] [Related]
11. Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.
Price RL; Chiocca EA
Neurosurgery; 2014 Aug; 61 Suppl 1(0 1):74-83. PubMed ID: 25032534
[No Abstract] [Full Text] [Related]
12. Chimeric HCMV/HSV-1 and Δγ
Ghonime MG; Jackson J; Shah A; Roth J; Li M; Saunders U; Coleman J; Gillespie GY; Markert JM; Cassady KA
Transl Oncol; 2018 Feb; 11(1):86-93. PubMed ID: 29216507
[TBL] [Abstract][Full Text] [Related]
13. Experimental therapy of human glioma by means of a genetically engineered virus mutant.
Martuza RL; Malick A; Markert JM; Ruffner KL; Coen DM
Science; 1991 May; 252(5007):854-6. PubMed ID: 1851332
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.
Chiocca EA; Nakashima H; Kasai K; Fernandez SA; Oglesbee M
Mol Ther Methods Clin Dev; 2020 Jun; 17():871-893. PubMed ID: 32373649
[TBL] [Abstract][Full Text] [Related]
16. Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?
Herbein G; Nehme Z
Mol Ther Oncolytics; 2020 Jun; 17():1-8. PubMed ID: 32300639
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways.
Tomita Y; Kurozumi K; Yoo JY; Fujii K; Ichikawa T; Matsumoto Y; Uneda A; Hattori Y; Shimizu T; Otani Y; Oka T; Kaur B; Date I
Mol Cancer Ther; 2019 Aug; 18(8):1418-1429. PubMed ID: 31092561
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Jahan N; Lee JM; Shah K; Wakimoto H
Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
20. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
